RAD51D: Options for Cancer Treatment
Cancer Treatment for People with Inherited Mutations
Testing positive for an inherited RAD51D mutation may affect your treatment options or eligibility for clinical trials studying which treatments work best. The following are examples of situations where an RAD51D mutation may play a part in treatment decision-making.
Targeted therapies for advanced cancers
PARP inhibitors are a type of that work by blocking a protein used to repair damaged . People with a RAD51D mutation who have been diagnosed with cancer may want to ask their doctor about whether they might benefit from therapy or a PARP inhibitor research study.
PARP inhibitors for advanced ovarian, or primary peritoneal cancer
Several PARP inhibitors have been approved to treat ovarian cancers at different stages of the disease. In some situations, a tumor known as an test ("") can help identify which ovarian cancers may respond to treatment with a PARP inhibitor.
after treatment
- HRD testing can help people with advanced ovarian cancer learn if they may benefit from the PARP inhibitor, Lynparza () in combination with Avastin (bevacizumab) as maintenance therapy after first-line platinum chemotherapy.
- () is approved for maintenance therapy in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who had a complete or partial response to first-line platinum-based chemotherapy. Zejula for maintenance therapy does not require an HRD test.
Maintenance therapy after treatment of recurrent cancer
- Zejula, () and Lynparza are all approved for maintenance therapy in people with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy. In this setting, none of these drugs requires an HRD test.
To learn more about treatment options for specific types of cancer, visit our section on cancer treatment by cancer type.
PARP inhibitors or other targeted therapies for advanced cancers with no other treatment options
If you have a RAD51D mutation and another type of advanced cancer that no longer responds to standard therapy, you may want to talk with your doctor about whether you might benefit from treatment with a PARP inhibitor or participation in a clinical trial.
In the News
Participate in Research
More Resources
Participate in Treatment Research
The treatment studies below are enrolling people with RAD51D mutations. To search for more studies, visit our Search and Enroll Tool.
